Rosacea-Specific Quality of Life Scale (RosaQoL): The Study of Adaptation and Validation for Turkish Rosacea Patients

Year 2022, , 999 - 1004, 30.12.2022

Mustafa Tosun , Yalçın Karagöz

https://doi.org/10.33808/clinexphealthsci.978423

Cited By: 1

Abstract

Objective: Rosacea-Specific Quality of Life Scale (RosaQoL) developed specifically for rosacea. The aim of the study was to adapt the RosaQoL Scale that is specific to Rosacea used in evaluating the quality of life of patients with Rosacea into Turkish, and evaluate its validity and reliability.
Methods: The RosaQoL Scale is a 21-item index that is specific to Rosacea, and was developed originally in English. The Turkish Scale, which was created after the clinical examinations of the patients, was applied to the patients. A total of 285 people, 240 females (84.2%) and 45 males (15.8%), who were diagnosed with Rosacea, admitting to the dermatology clinic between May 2019 and August 2019 were included in the study.
Results: The mean age of the patients was found to be 44.8 ± 12.5 years in the study. The internal consistency of the scale (Cronbach’s Alpha Coefficient) was found to be 0.952. The correlation coefficient was calculated as r=0.988 in the test-retest reliability. The total RosaQoL score
was 62.4 ± 11.5 (Mean ± SD), and the total DLQI score was 7.85 ± 5.04 (Mean ± SD). For validity analysis, the correlation coefficient between RosaQoL and DLQI was calculated as r=0.411 (p<0.05).
Conclusion: The Turkish version of the RosaQoL was valid and reliable for evaluating the quality of life of Turkish Rosacea patients.

Keywords

Quality of life, turkish version, validation, reliability, rosacea

References

• [1] Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol 2013; 69(6):27-35.
• [2] Hampton PJ. Expanding treatment options for rosacea. Br J Dermatol 2020;183(3):412-413.
• [3] Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, Powell F. Standard classification of rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol 2002;46:584-587.
• [4] Karabulut AA. Rozase ve yaşam kalitesi. Sarıcaoğlu H, Unal I, Karaman G, Ferahbaş Kesikoğlu A, Karadağ AS, Şikar Aktürk A, Kalkan G, editors. Rozase, Akne ve Rozase Tanı ve Tedavi. İstanbul: Galenos Yayınevi; 2018.p.450-461.(Turkish)
• [5] Prinsen CA, de Korte J, Augustin M, Sampogna F, Salek SS, Basra MK, Holm EA, Nijsten TE, EADV Taskforce on Quality of Life. Measurement of health-related quality of life in dermatological research and practice: outcome of the EADV Taskforce on Quality of Life. J Eur Acad Dermatol Venereol 2013;27(10):1195–1203.
• [6] Basra MKA, Finlay AY. Impact of rosacea on quality of life. In Pathogenesis and Treatment of Acne and Rosacea. Berlin: Heidelberg: Springer; 2014.p.743-747.
• [7] Dogramaci AC, Havlucu DY, Inandi T, Balkrishnan R. Validation of a melasma quality of life questionnaire for the Turkish language: the MelasQoL-TR study. J Dermatolog Treat 2009;20(2):95-99.
• [8] Nicholson K, Abramova L, Chren MM, Yeung J, Chon SY, Chen SC. A pilot quality-of-life instrument for acne rosacea. J Am Acad Dermatol 2007;57(2):213-221.
• [9] Tannus FC, Picosse FR, Soares JM, Bagatin E. Rosacea-specific quality of life questionnaire: translation, cultural adaptation and validation for Brazilian Portuguese. An Bras Dermatol 2018;93(6):836-842.
• [10] Deng Y, Peng Q, Yang S, Jian D, Wang B, Huang Y, Xie H, Li J. The Rosacea-specific Quality-of-Life instrument (RosQol): Revision and validation among Chinese patients. PloS one 2018;13(2):e0192487.
• [11] Finlay AY, Khan G. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19(3):210-216.
• [12] Öztürkcan S, Ermertcan AT, Eser E, Şahin MT. Cross validation of the Turkish version of dermatology life quality index. Int J Dermatol 2006;45(11):1300-1307.
• [13] Searle T, Al-Niaimi F, Ali FR. Rosacea and the cardiovascular system. J Cosmet Dermatol 2020;19(9):2182-2187.
• [14] Holmes AD, Spoendlin J, Chien AL, Baldwin H, Chang ALS. Evidence-based update on rosacea comorbidities and their common physiologic pathways. J Am Acad Dermatol 2018;78:156-166.
• [15] Finlay AY. Quality of life indices. Indian J Dermatol Venereol Leprol 2004;70(3):143-148